Related Experiment Videos

Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population

Nehal Mehta1, Muredach Reilly

  • 1Cardiovascular Division, Department of Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA.

HIV Clinical Trials
|March 15, 2005
PubMed

Insights

Atherosclerotic cardiovascular disease (CVD) is a growing concern for HIV patients due to therapy-related risks like dyslipidemia and inflammation. New markers help manage these complications and reduce CVD risk in HIV-positive individuals.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Metabolic Disorders

Background:

  • Atherosclerotic cardiovascular disease (CVD) is a major health issue globally and increasingly affects HIV-infected patients.
  • HIV infection and its treatment (highly active antiretroviral therapy, HAART) are associated with CVD risk factors such as insulin resistance, metabolic dyslipidemia, and inflammation.

Purpose of the Study:

  • To review the mechanisms of atherosclerotic CVD in the context of HIV infection.
  • To discuss established and emerging risk factors and markers for CVD in HIV-positive individuals.
  • To guide HIV physicians in managing metabolic complications and reducing CVD risk.

Main Methods:

  • Literature review of mechanisms, risk factors, and markers of atherosclerotic CVD.
  • Analysis of associations between HIV, HAART, metabolic complications, and CVD.
  • Discussion of clinical application of new risk markers like metabolic syndrome and C-reactive protein.

Main Results:

  • HIV therapy, particularly HAART, can contribute to atherogenic dyslipidemia, a known CVD risk factor.
  • Insulin resistance and inflammation are key mechanisms linking HIV disease and therapy to increased CVD risk.
  • Emerging markers like metabolic syndrome and C-reactive protein offer tools for risk stratification.

Conclusions:

  • Effective management of metabolic complications associated with HIV and HAART is crucial for reducing CVD risk.
  • Utilizing updated risk assessment tools, including new markers, can help clinicians optimize treatment regimens.
  • A comprehensive approach integrating CVD risk management is essential for HIV-positive patients.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...